In a recent meta-analysis of three adjuvant randomized trials with postmenopausal early-stage BC, Bartlett et al. [13] showed that patients with HR+/HER2 − BC benefited more from upfront AI compared to TAM in the adjuvant setting, whereas upfront AI in HR+/HER2 + BC did not seem to provide any additional benefit compared to TAM. This evidence concerns the gene ERBB2 and breast cancer.